National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost effectiveness of Fingolimod (Gilenya®) for the treatment of highly active relapsing-remitting multiple sclerosis.

Rapid Review

Commenced Completed Outcome
03/12/10 January 2011 Full Pharmacoeconomic Evaluation recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
03/06/11 20/09/11 Reimbursement not recommended at the submitted price

22nd September 2011

Following a price revision we now consider Fingolimod (Gilenya®) a cost-effective therapy for the treatment of relapsing-remitting multiple sclerosis patients in the Irish healthcare setting.

Fingolimod (Gilenya) summary